PARAMUS, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today that its Chief Medical Officer, Dr. Jamie Oliver, Pharm.D., will present in an upcoming Labroots webinar sponsored by Primetech Corporation on October 29, 2025, at 7:00 AM PDT / 10:00 AM EDT / 11:00 PM JST.
The webinar, titled “Development of a Low-Dose Percutaneous Delivery System for Lenalidomide in Hematologic Malignancies — The Journey from Idea to Impact,” will provide a detailed look at Starton’s innovative approach to continuous, low-dose percutaneous delivery of lenalidomide. Using Primetech’s iPRECIO® programmable pumps, Starton’s team was able to optimize pharmacokinetics, reduce toxicities, and improve translational relevance from preclinical studies to early clinical development.
Webinar Title: Development of a Low-Dose Percutaneous Delivery System for Lenalidomide in Hematologic Malignancies — The Journey from Idea to Impact
Featured Speaker: Dr. Jamie Oliver, Pharm.D., Chief Medical Officer, Starton Therapeutics
Date: October 29, 2025
Time: 7:00 AM PDT / 10:00 AM EDT / 11:00 PM JST
Webinar Highlights:
- Scientific rationale for continuous, low-dose lenalidomide delivery
- Preclinical modeling and translational strategies
- Pharmacokinetic and pharmacodynamic optimization
- Lessons learned from concept to early clinical development
Registration: Register for the webinar here.
Abstract
This presentation explores the scientific rationale, preclinical validation, and early clinical translation of STAR-LLD—a novel, continuous low-dose percutaneous lenalidomide delivery system for hematologic malignancies, with a focus on multiple myeloma (MM). Conventional oral lenalidomide regimens are constrained by rapid drug clearance, high peak plasma concentrations, and dose-limiting hematologic toxicities. STAR-LLD leverages subcutaneous infusion technology to maintain plasma concentrations above the minimum effective threshold for immune activation (≥0.04–0.1 µM/L), targeting sustained Ikaros/Aiolos protein degradation and optimal immunomodulatory activity.
Key preclinical studies in murine xenograft MM models demonstrated that continuous subcutaneous lenalidomide at 144 µg/day achieved superior tumor control (81% reduction in tumor volume) and prolonged time to treatment failure compared to standard daily bolus dosing, with no dose-limiting toxicities or significant hematologic suppression. Chronic dosing in healthy mice confirmed the absence of neutropenia, thrombocytopenia, or local tissue toxicity, supporting a favorable safety profile. Phase 1 clinical data in relapsed/refractory MM patients revealed that continuous subcutaneous STAR-LLD at 400 µg/h (9.6 mg/day) achieved >92% bioavailability, stable plasma concentrations above the biologically active range, and a >90% reduction in Cmax and ~57% lower AUC versus oral dosing. Notably, no Grade 3–4 hematologic toxicities were observed, and all patients achieved an objective response (1 CR, 5 PR), suggesting an improved therapeutic index and reduced risk of treatment-limiting cytopenia’s.
Learning Objectives:
- Understand the rationale and scientific basis for continuous low-dose lenalidomide delivery in hematologic malignancies, including the pharmacokinetic and pharmacodynamic advantages over conventional oral dosing.
- Evaluate preclinical and early clinical data supporting the efficacy and safety of STAR-LLD and recognize the implications for patient outcomes and future therapeutic strategies.
- Identify the translational steps and regulatory considerations involved in advancing STAR-LLD from preclinical models to Phase 2 clinical trials.
- This session is ideal for clinicians, researchers, and industry professionals interested in drug delivery innovation, myeloma therapeutics, and translational oncology.
About Primetech Corporation / iPRECIO®
Primetech Corporation develops iPRECIO® programmable infusion pumps, enabling automated, continuous, and variable dosing in freely moving animals to support reproducible preclinical research and translational studies. Learn more at www.iprecio.com.
About Labroots
Labroots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities.
Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. We have become a primary source for trending scientific news, webinars, virtual conferences and more. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.
Labroots webinars offer live, interactive sessions with expert speakers in life sciences, biotechnology, and healthcare, providing an accessible platform for learning, networking, and exploring emerging technologies. Learn more at www.labroots.com.
About STAR-LLD
STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD with 20% of animals in this cohort tumor-free after 100 days; by contrast, there was a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The Phase 1b clinical study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity.
About Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton’s proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit www.startontx.com.
Forward Looking Statements
All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and, except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Investor Relations Contact
Alex Starr
Managing Director
LifeSci Advisors
[email protected]
